Isabelle Mahé: Reduced-Dose Apixaban Lowers Bleeding Risk in CAT Without Losing Efficacy
Isabelle Mahé, Head of Internal Medicine at the Louis Mourier Hospital, APHP at Paris Cité University, shared a post on LinkedIn about several recent articles she and her colleagues co-authored, adding:
”In patients with CAT receiving extended treatment, reduced-dose apixaban is non inferior to full dose apixaban, and is associated with a significant 25% reduction in the risk of Clinically Relevant Bleeding․
4 clinical predictors were significantly associated with increased CRB risk:
- anaemia and/or
- thrombocytopenia,
- age ≥75, PE as the index event,
- male sex (The Lancet Haematology)․
The accumulation of bleeding risk predictors emerged as a major determinant of clinically relevant bleeding, with consistent patterns across dosing regimens. (The Lancet Haematology)․
In patients with bleeding risk predictors, a lower clinically relevant bleeding with reduced-dose apixaban was observed.
Those data reinforce the clinical relevance of the API-CAT findings, including for patients with non-modifiable bleeding risk factors․
Please read our reply just published in The Lancet Haematology!”
Title 1: Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism
Authors: Isabelle Mahé, Marc Carrier, Didier Mayeur, Jean Chidiac, Eric Vicaut, Nicolas Falvo, Olivier Sanchez
Read the Full Article on The New England Journal of Medicine․
Title 2: Predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated venous thromboembolism (API-CAT): a post-hoc analysis of a randomised, non-inferiority trial
Authors: Isabelle Mahé, Céline Chapelle, Philippe Girard, Marc Carrier, Luis Jara Palomares, Charles-Marc Samama, Hélène Helfer, Grigoris Gerotziafas, Silvy Laporte, Eric Vicaut, Patrick Mismetti
Read the Full Article on The Lancet Haematology․
Title 3: Predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated VTE – Authors’ reply
Authors: Isabelle Mahé, Céline Chapelle, Silvy Laporte
Read the Full Article on The Lancet Haematology․
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 22, 2026, 11:03Frailty and Healthy Aging in People With Hemophilia – JTH
-
Oct 22, 2026, 10:53Divyaswathi Citla-Sridhar: Immune Risks Following Gene Therapy for Hemophilia A
-
Oct 22, 2026, 10:01Matthew Hazell: AABB 2026 – Beyond the Antibody Screen in Complex Immunohematology Reference Testing
-
Oct 22, 2026, 09:54Dr. Geoffrey Barnes Highlights Blood Clot Risks Following NFL Star Jalen Hurts’ Diagnosis – ISTH
-
Oct 22, 2026, 09:45Louise St. Germain Bannon: Closing the Awareness Gap in Women’s Health and Blood Clot Risks
-
Oct 22, 2026, 09:37Raghavendra Rao: Where Does the Great Saphenous Vein Terminate? Test Your Anatomy Knowledge
-
Oct 22, 2026, 09:32Gashaw Arega Mekonnen: Expansion of Pediatric Hematology and Oncology Services in Ethiopia
-
Oct 22, 2026, 09:23World Thrombosis Day Walk on a Beautiful Morning in Auckland – THANZ
-
Oct 22, 2026, 06:43Giacomo Buso: Lifelong Carotid Risk vs. Late-Stage Trial Neutrality